TherapeuticsMD (TXMD) Net Income towards Common Stockholders Growth (1y) (2011 - 2026)
Powered by 
Analysis
TherapeuticsMD (TXMD) Net Income towards Common Stockholders Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | -0.05% |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | 284.27% |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | -130.19% |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | -19.23% |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | -108.13% |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | 152.55% |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | -91.06% |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | 151.28% |
| 10 | TherapeuticsMD | 25.35 Mn | 16.16 Mn | - | -71.87% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -71.87% |
| Mar 31, 2026 | 114.55% |
| Dec 31, 2025 | -241.11% |
| Sep 30, 2025 | 124.96% |
| Jun 30, 2025 | 147.71% |
| Mar 31, 2025 | 11.04% |
| Dec 31, 2024 | 144.92% |
| Sep 30, 2024 | 81.97% |
| Jun 30, 2024 | 52.15% |
| Mar 31, 2024 | 79.63% |
| Dec 31, 2023 | -101.19% |
| Sep 30, 2023 | 88.22% |
| Jun 30, 2023 | -102.16% |
| Mar 31, 2023 | 92.65% |
| Dec 31, 2022 | 54.94% |
| Sep 30, 2022 | 39.55% |
| Jun 30, 2022 | 361.84% |
| Mar 31, 2022 | -24.47% |
| Dec 31, 2021 | 219.16% |
| Sep 30, 2021 | -45.41% |